Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sunesis Pharmaceuticals, Inc.    SNSS

SUNESIS PHARMACEUTICALS, INC.

(SNSS)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

SUNESIS PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 05:30pm EDT

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or

Standard; Transfer of Listing.

On January 11, 2019, Sunesis Pharmaceuticals, Inc., or the Company, received a letter from the Listing Qualifications Department, or the Staff, notifying the Company that in accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has been granted an additional 180 calendar days, or until July 10, 2019, to regain compliance with the minimum $1.00 per share requirement for continued inclusion on The NASDAQ Capital Market pursuant to NASDAQ Listing Rule 5550(a)(2), or the Rule. If, at any time before July 10, 2019, the bid price of the Company's common stock closes at $1.00 or more for a minimum of ten consecutive business days as required under NASDAQ Listing Rule 5810(c)(3)(A), unless the Staff exercises its discretion to extend this ten-day period pursuant to NASDAQ Listing Rule 5810(c)(3)(F), the Staff will provide written notification to the Company that it complies with the Rule.

If the Company does not regain compliance with the Rule by July 10, 2019, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a NASDAQ Hearings Panel, or the Panel. The Company would remain listed pending the Panel's decision. There can be no assurance that, if the Company does appeal the delisting determination by the Staff to the Panel, that such appeal would be successful.

The Company is considering actions that it may take in response to this notification in order to regain compliance with the continued listing requirements.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SUNESIS PHARMACEUTICALS, I
06/17SUNESIS PHARMACEUTICALS : Announces Presentation of Preliminary Data from Phase ..
AQ
06/15Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase..
GL
06/06SUNESIS PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holder..
AQ
05/08SUNESIS : 1Q Earnings Snapshot
AQ
05/08SUNESIS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
05/08SUNESIS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
AQ
05/08Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Rece..
GL
05/01Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Q..
GL
04/29SUNESIS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Termin..
AQ
04/29Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Mill..
GL
More news
Financials ($)
Sales 2019 0,49 M
EBIT 2019 -27,2 M
Net income 2019 -28,2 M
Debt 2019 0,03 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 106x
EV / Sales 2020 4,00x
Capitalization 51,9 M
Chart SUNESIS PHARMACEUTICALS, INC.
Duration : Period :
Sunesis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUNESIS PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 5,17 $
Spread / Average Target 622%
EPS Revisions
Managers
NameTitle
Dayton Misfeldt Chief Executive Officer & Director
James W. Young Non-Executive Chairman
Deepali Suri Vice President-Clinical Operations
Willie P. Quinn CFO, Senior VP-Finance & Corporate Development
Judith A. Fox Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
SUNESIS PHARMACEUTICALS, INC.87.59%55
IQVIA HOLDINGS INC21.76%26 223
LONZA GROUP31.53%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION28.70%17 061
EXACT SCIENCES CORPORATION77.35%13 037